证券代码：688506 证券简称：百利天恒 公告编号：2025-045 公司本次向特定对象发行 A 股股票事项尚需通过上交所审核，并获得中国证券 监督管理委员会（以下简称"中国证监会"）作出同意注册的决定后方可实施，最终 能否通过上交所审核，并获得中国证监会同意注册的决定及其时间尚存在不确定性。 公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投资者注意投 资风险。 特此公告。 2025 年 6 月 14 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川百利天恒药业股份有限公司（以下简称"公司"）于 2025 年 4 月 30 日收 到上海证券交易所（以下简称"上交所"）出具的《关于四川百利天恒药业股份有 限公司向特定对象发行股票申请文件的审核问询函》（上证科审（再融资）〔2025〕 47 号）（以下简称"《审核问询函》"），上交所审核机构对公司向特定对象发行股 票申请文件进行了审核，并形成了问询问题。 公司收到《审核问询函》后，按照要求会同相关中介机构就《审核问询函》提 出的问题进行了认真研究和逐项落实， ...

关于四川百利天恒药业股份有限公司 2025 年度向特定对象发行 A 股股票 申请文件的审核问询函的回复报告 （修订稿） 保荐人（主承销商） （广东省深圳市福田区中心三路8号卓越时代广场（二期）北座） 二〇二五年六月 上海证券交易所： 贵所于2025年4月30日出具的《关于四川百利天恒药业股份有限公司向特定 对象发行股票申请文件的审核问询函》（上证科审（再融资）〔2025〕47号） （以下简称"审核问询函"）已收悉，四川百利天恒药业股份有限公司（以下 简称"百利天恒""发行人"或"公司"）与中信证券股份有限公司（以下简 称"中信证券""保荐人"或"保荐机构"）、立信会计师事务所（特殊普通 合伙）（以下简称"申报会计师"）等相关方已就审核问询函中提到的问题进 行了逐项落实并回复。 如无特别说明，本回复报告中的简称或名词的释义与《四川百利天恒药业 股份有限公司2025年度向特定对象发行A股股票募集说明书》中的含义相同。 本回复报告部分表格中单项数据加总与合计数据可能存在微小差异，均系计算 过程中的四舍五入所致。 | 黑体（加粗） | 审核问询函所列问题 | | --- | --- | | 宋体（不加粗） | 对审核 ...

Core Viewpoint - The article emphasizes the importance of hard technology companies in supporting national strategies and achieving high-level technological self-reliance, particularly for quality unprofitable enterprises that can transform with quality capital empowerment [1][2]. Group 1: Policy Support and Market Dynamics - The China Securities Regulatory Commission (CSRC) released the "Eight Measures for Deepening the Reform of the Sci-Tech Innovation Board" on June 19, 2024, which supports unprofitable enterprises with key core technologies and significant market potential to go public [1][2]. - As of May 2025, the Sci-Tech Innovation Board has supported 54 unprofitable companies in their IPOs, covering emerging industries such as innovative pharmaceuticals, chip design, and artificial intelligence, with a total revenue of 174.48 billion yuan in 2024, a 24% year-on-year increase [1][5]. - The implementation of new regulations allows for different lock-up ratios or periods for offline investors in unprofitable companies, shifting the investment logic from short-term profit to long-term value [4]. Group 2: Financial Performance and Growth - In 2024, the 54 unprofitable companies on the Sci-Tech Innovation Board achieved a total revenue exceeding 170 billion yuan, with a 24% year-on-year growth, while their net losses decreased by 36% [5][10]. - Notable companies like SMIC and Kingsoft Office reported revenue and net profit growth of 21.2% and 24.3% respectively in 2024, showcasing significant development since their IPOs [5][10]. - The total R&D investment of the 54 unprofitable companies reached 45.944 billion yuan in 2024, marking a 5.86% increase, with a median R&D investment-to-revenue ratio of 37.74%, significantly higher than the board's median of 12.64% [6]. Group 3: Case Studies of Successful Companies - Baile Tianheng, a notable unprofitable company, has seen its stock price rise from 24.7 yuan at IPO to 338 yuan, demonstrating successful growth and a robust pipeline of innovative drugs [6][7]. - Tianyue Advanced, another unprofitable company, utilized its IPO proceeds to enhance its production capacity in silicon carbide semiconductor materials, showcasing effective capital market utilization for technological advancement [7][8]. Group 4: Future Outlook and Investor Engagement - Companies are focusing on sustainable profitability and balancing technological investments to enhance market value and investor confidence [11]. - The number of Sci-Tech themed ETFs has doubled since the release of the "Eight Measures," indicating growing investor interest and potential in the sector [10].

Core Viewpoint - The performance of the Sci-Tech Innovation Pharmaceutical Index ETF has shown significant growth in both trading volume and scale, indicating strong investor interest and confidence in the sector [3][5][6]. Liquidity - The Sci-Tech Innovation Pharmaceutical Index ETF had an intraday turnover of 9.12%, with a transaction volume of 20.17 million yuan. Over the past week, the average daily transaction volume reached 50.98 million yuan, ranking first among comparable funds [3]. Scale - In the past year, the Sci-Tech Innovation Pharmaceutical Index ETF's scale increased by 143 million yuan, achieving notable growth and ranking first among comparable funds [3]. Shares - The ETF's shares grew by 120 million in the past year, also ranking first among comparable funds [3]. Top Holdings - As of May 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 51.6% of the total weight. The leading stocks include: - United Imaging Healthcare (8.97%) - BeiGene (7.05%) - Huaitai Medical (5.85%) - Aierx (4.91%) - Baillie Tianheng (4.77%) - Zai Lab (4.75%) - BGI Genomics (4.17%) - Junshi Biosciences (4.15%) - Aibo Medical (3.33%) - Teva Biopharma (3.25%) [5]. Market Response - Following the American Society of Clinical Oncology (ASCO) annual meeting, there has been a positive market response, highlighting the competitiveness and innovation of Chinese pharmaceutical companies in new drug development [5][6]. Innovation Pipeline - The proportion of domestic companies' innovative drug data presented at ASCO has been increasing, with 73 studies selected for oral presentations in 2025, indicating a strong focus on innovation within the industry [6]. Investment Opportunities - Investors without stock accounts can access opportunities in the Sci-Tech Innovation Board biopharmaceutical sector through the Sci-Tech Biopharmaceutical ETF linked fund (021061) [6].

截至2025年6月9日 11:07，创新药企ETF(560900)上涨3.86%，盘中换手9.64%，成交311.37万元。跟踪指 数中证创新药产业指数(931152)强势上涨3.77%，成分股百利天恒(688506)上涨10.71%，众生药业 (002317)上涨9.99%，百济神州(688235)上涨8.14%，迪哲医药(688192)，信立泰(002294)等个股跟涨。 信达证券表示， ADA会议是中国创新药企业向海外展示GLP-1领域研发实力的重要窗口，有望带动 GLP-1 产业链相关行情。在CXO 和生命科学上游产业链方面，创新药企业投融资修复及授权BD获得的 资金，有望带动药企加码研发投入并加速研发项目推进速度。 中信建投证券指出，创新药方面，近期研发突破及新药获批上市驱动创新药板块表现强劲，中国创新药 在全球市场展现出强大的竞争力。 创新药企ETF紧密跟踪中证创新药产业指数，中证创新药产业指数从主营业务涉及创新药研发的上市公 司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映创新药产业上市公司证券的 整体表现。 伴随AI驱动新一轮科技浪潮的兴起，摩根资产管理整合旗下"全球视野投 ...

Group 1 - During the period from June 2 to June 6, 141 listed companies disclosed institutional research minutes, with over 70% of the companies experiencing positive stock performance, notably Jinling Sports with an increase of 88.24% [1] - Baili Tianheng attracted 136 institutional inquiries, focusing on its self-developed EGFRXHER3 dual-target ADC drug, iza-bren, which showed excellent data in lung cancer treatment, particularly in patients previously treated with PD-(L)1 inhibitors combined with platinum-based chemotherapy [3] - Zhongke Chuangda received 130 institutional inquiries, with a focus on its mobile robot product series, which has rapidly developed in scenarios such as latent robots, unmanned forklifts, and inspection robots, aiming to deepen its logistics and manufacturing sectors [3] Group 2 - Zhongqi New Materials addressed institutional concerns regarding industry integration and future asset acquisitions, indicating a structured approach to support the development of semiconductor materials and the integration of high-end equipment with existing materials business [4] - The company plans to enhance traditional materials technology and explore collaborations with Xingkong Technology to create synergistic effects [4]

本周(6月2日—6月6日)资金情绪持续回暖，A股市场连日上涨，上证指数全周上涨1.13%，收于3385.36 点；深证成指涨1.42%，创业板指上涨2.32%。 盘面上，本周申万一级行业均实现上涨，其中通信以5.7%的涨幅领涨各行业，有色金属、轻工制造、 电子、计算机等行业涨幅居前，交通运输、钢铁、汽车等行业涨幅相对较小。主题题材上，光模块 (CPO)、光通信、稀土、数字货币等行业表现活跃。 本周机构调研公司数量仍在百家以上，截至6月6日18时，共有141家上市公司披露机构调研纪要。在赚 钱效应方面，本周超七成机构调研公司股价实现正收益，金陵体育（300651）以88.24%的涨幅领先， 联化科技（002250）股价累计上涨39.13%，超捷股份（301005）、乐惠国际（603076）、瑞晟智能股 价均涨超20%，盛达资源（000603）、楚天龙（003040）等公司周内实现首板。 从热门调研标的来看，百利天恒、中科创达（300496）周内接受百家以上机构调研，中旗新材 （001212）、福莱新材（605488）、燕京啤酒（000729）、宇信科技（300674）、海创药业-U等5家公 司获得超50家机构关 ...

Core Viewpoint - The company, Baili Tianheng, recently held an investor conference to discuss its clinical data presented at the 2025 ASCO conference, recent business developments, and investor inquiries regarding its innovative drug pipeline and clinical trials [1][3][4]. Group 1: ASCO Conference Data - At the 2025 ASCO conference, the company presented impressive clinical data for its core product, iza-bren (BL-B01D1), demonstrating significant efficacy in NSCLC and SCLC patients with non-classical EGFR mutations [4]. - In NSCLC, iza-bren showed an overall objective response rate (ORR) of 46.2% and a disease control rate (DCR) of 85.9% among 78 patients, with a median progression-free survival (mPFS) of 7 months [4]. - In SCLC, among 58 patients, the ORR was 55.2%, with a DCR of 81% and a median overall survival (mOS) of 12 months [5]. Group 2: Drug Development Pipeline - The company has a diversified innovative drug pipeline, including 9 clinical assets based on its ADC platform, 4 drugs in clinical trials from its multi-specific antibody (GNC) platform, and one asset (SI-B001) in Phase III trials from its bispecific antibody platform [2][6][7]. - The company is conducting multiple clinical trials for iza-bren in the U.S., including a Phase I trial with a target enrollment of 260 patients and a Phase II/III trial for triple-negative breast cancer [7][10]. Group 3: Investor Q&A Highlights - The company expressed confidence in the consistency of clinical data for iza-bren between China and the U.S., noting similar safety profiles and manageable toxicity [8]. - The collaboration with Bristol-Myers Squibb (BMS) for iza-bren's development involves shared responsibilities in the U.S. while retaining exclusive rights in China [8]. - The company is expanding its clinical plans for NSCLC and SCLC, with ongoing Phase III trials and plans for future registration trials based on promising early data [9][10].

以下文章来源于21新健康 ，作者季媛媛，韩利明 21新健康 . 21世纪传媒 · 公众号矩阵成员。 作 者丨季媛媛 韩利明 昨天，百利天恒（688506.SH）股价创阶段新高，而在5月30日该股收盘市值首次突破1200亿 元。2024年和2025年至今，百利天恒的股票涨幅分别达37%和56%。 持有百利天恒股票达 74.35%的董事长朱义，个人身家也涨至近900亿元，稳坐四川富豪头把交椅。 朱义财富快速飙升，源于一年半前的一笔大买卖。 2023年12月12日，一项足以撼动全球医药界的交易在中国低调完成。百利天恒与全球制药巨 头百时美施贵宝（BMS）签订了关于BL-B01D1的授权协议， 潜在总交易额高达84亿美元。 在那个被业界称为"资本寒冬"的严酷时期，这场交易犹如一声惊雷，唤醒了沉寂的医药市 场。 消息一出，上海张江药谷的众多办公室彻夜灯火通明。有创业者不断刷新手机屏幕以确认消 息的真实性，有投资人连夜召开紧急会议，重新评估行业赛道的价值。84亿美元——这一数 字不仅刷新了中国创新药BD交易的首付款及总金额纪录，更标志着一个新时代的到来：中国 本土研发的双特异性抗体药物（ADC）首次成功走向国际市场。 " ...

Core Viewpoint - The significant rise in the stock price of Baili Tianheng (688506.SH) and the wealth of its chairman, Zhu Yi, is primarily attributed to a groundbreaking licensing agreement with Bristol-Myers Squibb (BMS) for the drug BL-B01D1, with a potential total transaction value of $8.4 billion [2][3][11]. Company Overview - Baili Tianheng's stock price surged by 5.31% on May 30, 2023, marking a market capitalization exceeding 120 billion yuan for the first time [1]. - The stock has seen increases of 37% and 56% in 2024 and 2025, respectively [1]. - Zhu Yi holds a 74.35% stake in Baili Tianheng, with his personal wealth rising to nearly 90 billion yuan, making him the richest person in Sichuan [1]. Strategic Developments - The licensing agreement with BMS, completed on December 12, 2023, is a landmark deal that revitalized the pharmaceutical market in China, marking the first successful international venture for a locally developed bispecific antibody drug [2][3]. - This deal not only set records for upfront and total transaction amounts in China's innovative drug business but also signifies China's growing influence in the global pharmaceutical sector [3]. Financial Implications - The agreement is expected to lead to explosive growth in Baili Tianheng's revenue and net profit in 2024, fundamentally altering the company's financial trajectory [3]. - Despite the influx of BD income, Baili Tianheng faces a significant funding gap for R&D and operations over the next three years, estimated at 4.819 billion yuan [13]. Capital Raising Initiatives - In response to funding needs, Baili Tianheng has initiated dual capital-raising strategies: applying for an IPO on the Hong Kong Stock Exchange and preparing for a targeted issuance in the A-share market [4][14]. - The IPO aims to leverage the mature valuation system of the Hong Kong market, while the A-share issuance is seen as a quicker way to raise capital [4]. R&D Focus - Baili Tianheng has significantly increased its R&D investment, from 181 million yuan in 2019 to 746 million yuan in 2023, with R&D expenses constituting 132.82% of its revenue in 2023 [10][11]. - The company has 15 candidate drugs in clinical stages and over 80 clinical trials globally, including multiple Phase III trials [13]. Industry Context - The Chinese innovative drug sector has seen a surge in original research, with the number of new drugs entering clinical trials surpassing that of the U.S. from 2015 to 2024 [15]. - The recent ASCO conference highlighted the achievements of Chinese companies in innovative drug research, showcasing a growing presence on the global stage [15][16].